The Latin America, Middle East and Africa Ulcerative Colitis Market is expected to witness market growth of 8.1% CAGR during the forecast period (2022-2028).
Ulcerative colitis is an inflammatory bowel disease (IBD) that produces inflammation and ulcers (sores) in the digestive tract, according to the report's description. The innermost lining of the large intestine (colon) and rectum are affected by ulcerative colitis. Symptoms usually appear gradually rather than abruptly. The focus on diagnosis and therapy to minimize and control the signs and symptoms of ulcerative colitis is driving up the demand for ulcerative colitis drugs. There is currently no permanent cure for Ulcerative Colitis, and the specific origin of the condition's onset is unknown. Several types of medications may be beneficial in the treatment of the symptoms. The sort of medication or therapy provided to a patient is mostly determined by the disease's aetiology and severity. The treatments given to people with the illness are mainly aimed at lowering swelling and inflammation, as well as maintaining a healthy diet, which helps to alleviate many of the symptoms.
Ulcerative colitis is said to be uncommon among black people in Sub-Saharan Africa. The majority of patients (72 percent) arrived with severe symptoms and substantial colonic involvement, according to this group of the first 46 patients treated at Baragwanath Hospital in Soweto. There's a dichotomy here: there are a lot of diseases, but there aren't many consequences that necessitate surgery. This is most likely owing to medical treatment, especially corticosteroid medication, altering the disease's natural history.
Moreover, an increase in inflammatory bowel disease risk factors such as smoking, drinking, sedentary lifestyle, and non-nutritious food consumption may increase the occurrence of inflammatory bowel disease, which is expected to help the regional market to expand further. Furthermore, the market is expected to develop due to comparatively permissive drug regulatory rules and increased government initiatives for healthcare reform. Some of the major trends of the regional market are increased healthcare expenditure and growing standards of living in the region. Therefore, these factors are estimated to propel the growth of the regional Ulcerative Colitis Market over the forecast period.
The Brazil market dominated the LAMEA Ulcerative Colitis Market by Country 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $134.5 million by 2028. The Argentina market is estimated to grow at a CAGR of 8.7% during (2022-2028). Additionally, The UAE market is expected to witness a CAGR of 7.8% during (2022-2028).
Based on Molecule Type, the market is segmented into Small Molecules and Biologics. Based on Disease Type, the market is segmented into Mild, Moderate, and Severe. Based on Route of Administration, the market is segmented into Oral and Injectables. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Abbott Laboratories, Ajinomoto Co., Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., InDex Pharmaceuticals Holding AB, and Eli Lilly And Company.
ByMolecule Type
By Country
Ulcerative colitis is an inflammatory bowel disease (IBD) that produces inflammation and ulcers (sores) in the digestive tract, according to the report's description. The innermost lining of the large intestine (colon) and rectum are affected by ulcerative colitis. Symptoms usually appear gradually rather than abruptly. The focus on diagnosis and therapy to minimize and control the signs and symptoms of ulcerative colitis is driving up the demand for ulcerative colitis drugs. There is currently no permanent cure for Ulcerative Colitis, and the specific origin of the condition's onset is unknown. Several types of medications may be beneficial in the treatment of the symptoms. The sort of medication or therapy provided to a patient is mostly determined by the disease's aetiology and severity. The treatments given to people with the illness are mainly aimed at lowering swelling and inflammation, as well as maintaining a healthy diet, which helps to alleviate many of the symptoms.
Ulcerative colitis is said to be uncommon among black people in Sub-Saharan Africa. The majority of patients (72 percent) arrived with severe symptoms and substantial colonic involvement, according to this group of the first 46 patients treated at Baragwanath Hospital in Soweto. There's a dichotomy here: there are a lot of diseases, but there aren't many consequences that necessitate surgery. This is most likely owing to medical treatment, especially corticosteroid medication, altering the disease's natural history.
Moreover, an increase in inflammatory bowel disease risk factors such as smoking, drinking, sedentary lifestyle, and non-nutritious food consumption may increase the occurrence of inflammatory bowel disease, which is expected to help the regional market to expand further. Furthermore, the market is expected to develop due to comparatively permissive drug regulatory rules and increased government initiatives for healthcare reform. Some of the major trends of the regional market are increased healthcare expenditure and growing standards of living in the region. Therefore, these factors are estimated to propel the growth of the regional Ulcerative Colitis Market over the forecast period.
The Brazil market dominated the LAMEA Ulcerative Colitis Market by Country 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $134.5 million by 2028. The Argentina market is estimated to grow at a CAGR of 8.7% during (2022-2028). Additionally, The UAE market is expected to witness a CAGR of 7.8% during (2022-2028).
Based on Molecule Type, the market is segmented into Small Molecules and Biologics. Based on Disease Type, the market is segmented into Mild, Moderate, and Severe. Based on Route of Administration, the market is segmented into Oral and Injectables. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Abbott Laboratories, Ajinomoto Co., Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., InDex Pharmaceuticals Holding AB, and Eli Lilly And Company.
Scope of the Study
Market Segments Covered in the Report:
ByMolecule Type
- Small Molecules
- Biologics
- Mild
- Moderate
- Severe
- Oral
- Injectables
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Ajinomoto Co., Inc.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Sanofi S.A.
- InDex Pharmaceuticals Holding AB
- Eli Lilly And Company
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. LAMEA Ulcerative Colitis Market by Molecule Type
Chapter 5. LAMEA Ulcerative Colitis Market by Disease Type
Chapter 6. LAMEA Ulcerative Colitis Market by Route of Administration
Chapter 7. LAMEA Ulcerative Colitis Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Ajinomoto Co., Inc.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Sanofi S.A.
- InDex Pharmaceuticals Holding AB
- Eli Lilly And Company
Methodology
LOADING...
